Floatz logo

Thiotepa

Chronic Myeloid Leukemia

Leland MethenySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2/3BB
Muromonab-Cd3
St. Jude Children's Research Hospital
Phase 3BB
Bendamustine
St. Petersburg State Pavlov Medical University
Phase 2B
Idarubicine
M.D. Anderson Cancer Center
Phase 2B
Azacitidine
The First Affiliated Hospital of Soochow University
Phase 2B

View all 44 →

Same molecule, other indications

Thiotepa is also rated in:

graft versus host diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →
juvenile myelomonocytic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →